Thailand scraps plan for 16-week dose gap on AstraZeneca vaccine
Reuters
Published Jun 18, 2021 08:50AM ET
BANGKOK (Reuters) - Thailand has abandoned its plan for a 16-week gap between doses of the AstraZeneca (NASDAQ:AZN) coronavirus vaccine and will opt for a shorter interval of 10 to 12 weeks instead, a senior health official said on Friday.
The government, which plans to use the AstraZeneca vaccine for most of its inoculations, had sought to reach more people faster by stretching the gap to 16 weeks, beyond the 12 weeks maximum approved by the European Medicines Agency.
A 16-week interval has not been tested in human trials.
But Sophon Mekthon, the public health minister's assistant, told Reuters Thailand's communicable disease committee wanted to revert to the previous interval, adding that it could still be extended in future if necessary.
Thailand started its mass COVID-19 immunisation campaign last week and has administered 7.2 million doses since February.
A royal-owned Thai firm has partnered with AstraZeneca to make its vaccine locally, but has experienced delays, also impacting Taiwan, Malaysia and the Philippines.
Health Minister Anutin Charnvirakul on Friday said the government would receive 10 million AstraZeneca doses monthly from July until its quota of 61 million doses is met. Thailand has also been using Sinovac's vaccine.
The rush for vaccines came as Thailand was hit by its most severe wave of coronavirus infections in early April, months before the start of its immunisation drive.
It has secured 105.5 million doses so far and will procure 50 million more next year, authorities have said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.